Medicus Pharma's SkinJect Phase 2 Trial Sees 73% Clearance Rate in 200-µg Arm.

Medicus Pharma announced that Dr. Babar K. Rao, an internationally recognized academic dermatologist, will provide clinical interpretation of positive Phase 2 data during a business update webcast on March 26. The study demonstrated 73% clinical clearance in the 200-µg arm, suggesting that approximately three out of four treated lesions may allow patients to avoid immediate surgical intervention. Dr. Rao is the Principal Investigator of the SKNJCT-003 clinical study, a randomized, double-blind Phase 2 trial evaluating the therapeutic contribution of doxorubicin delivered through the SkinJect microneedle platform in patients with nodular basal cell carcinoma.